Clinical Trials in Atlanta

Showing 2081-2100 of 16,968 trials

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

NCT05818553

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

SCN2A EncephalopathySCN8A Encephalopathy

Praxis Precision Medicines77 participantsStarted Aug 2023

Atlanta, Georgia, United States • Chicago, Illinois, United States • Minneapolis, Minnesota, United States +5 more locations

RECRUITINGPhase 1/2< 1 mile

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

NCT06055439

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.

Neuroendocrine TumorsColorectal CancerGastric Cancer

Chimeric Therapeutics135 participantsStarted May 2024

Atlanta, Georgia, United States • Chicago, Illinois, United States • Philadelphia, Pennsylvania, United States +1 more locations

COMPLETEDPhase 3< 1 mile

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05067127

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.

C3GIC-MPGNC3 Glomerulopathy+9 more

Apellis Pharmaceuticals, Inc.124 participantsStarted Nov 2021

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +122 more locations

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Find Trials by Condition in Atlanta

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Exploration of an Online Education Program to Support Caregivers' Knowledge Transfer

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.